Sponsors (10)
The bill would accelerate research, diagnosis, and public support for glioblastoma—potentially improving outcomes for patients—but does so at the risk of higher federal spending, possible diversion of research resources from other conditions, and increased short‑term costs or coverage disputes for patients.
Patients with glioblastoma could see faster development of new therapies because the bill expands support for preclinical and early‑phase clinical trials.
Hospitals and research institutions gain clearer justification to prioritize glioblastoma biomarker testing and diagnostic capacity, improving diagnosis and research capabilities.
Patients, caregivers, and researchers may benefit from greater public awareness that increases caregiver support, philanthropic donations, and clinical trial enrollment for glioblastoma research.
Taxpayers and federal budgets could face higher research spending if the bill increases funding for glioblastoma programs.
Researchers, health systems, and patients with other diseases could lose access to limited research resources if prioritizing glioblastoma leads to reallocation rather than net increases in research funding.
Patients could face higher short‑term out‑of‑pocket costs or insurance disputes because emphasis on biomarker testing and specialized diagnostics may not be fully covered.
Based on analysis of 1 section of legislative text.
Expresses congressional recognition of glioblastoma's severe burden, highlights diagnostic and treatment gaps, and encourages awareness and support for research and patients.
Official title: Designating July 15, 2026, as "Glioblastoma Awareness Day".
Introduced June 23, 2026 by Lindsey O. Graham · Last progress June 23, 2026
Recognizes the severe burden of glioblastoma in the United States, cites up-to-date statistics on incidence, mortality, and survival, and highlights gaps in screening, diagnostics, treatment approvals, and patient out‑of‑pocket costs. The resolution notes recent molecular diagnostic changes and existing NIH/NCI efforts such as the Glioblastoma Therapeutics Network and calls for greater public awareness and support for patients, caregivers, and research.